{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T23:37:46Z","timestamp":1785109066253,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,8,24]],"date-time":"2011-08-24T00:00:00Z","timestamp":1314144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s12282-011-0297-y","type":"journal-article","created":{"date-parts":[[2011,8,23]],"date-time":"2011-08-23T12:28:54Z","timestamp":1314102534000},"page":"329-334","source":"Crossref","is-referenced-by-count":15,"title":["A lower dose of docetaxel at 60\u00a0mg\/m2 could be continued longer for controlling peripheral edema in patients with metastatic breast cancer"],"prefix":"10.1007","volume":"19","author":[{"given":"Mari","family":"Hosonaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahomi","family":"Tokudome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,24]]},"reference":[{"key":"297_CR1","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","volume":"23","author":"SE Jones","year":"2005","unstructured":"Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;23:5542\u201351.","journal-title":"J Clin Oncol"},{"key":"297_CR2","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1200\/JCO.2005.05.0294","volume":"24","author":"V Harvey","year":"2006","unstructured":"Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol. 2006;24:4963\u201370.","journal-title":"J Clin Oncol"},{"key":"297_CR3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/oxfordjournals.annonc.a010544","volume":"7","author":"P Fumoleau","year":"1996","unstructured":"Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol. 1996;7:165\u201371.","journal-title":"Ann Oncol"},{"issue":"8","key":"297_CR4","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","volume":"17","author":"S Chan","year":"1999","unstructured":"Chan S, Friedrichs K, Noel D, Pinter T, Belle SV, Vorobiof D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999;17(8):2341\u201354.","journal-title":"J Clin Oncol"},{"issue":"5","key":"297_CR5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","volume":"17","author":"JM Nabholtz","year":"1999","unstructured":"Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 1999;17(5):1413\u201324.","journal-title":"J Clin Oncol"},{"issue":"9","key":"297_CR6","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.1997.15.9.3149","volume":"15","author":"MJ Piccart","year":"1997","unstructured":"Piccart MJ, Kliin J, Paridaens R, Nooii M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol. 1997;15(9):3149\u201355.","journal-title":"J Clin Oncol"},{"key":"297_CR7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2125.1997.00613.x","volume":"43","author":"A Behar","year":"1997","unstructured":"Behar A, Pujade-Lauraine E, Maurel A, Brun MD, Lagrue G, Feuilhade De Chauvin F, et al. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid. Br J Pharmacol. 1997;43:653\u20138.","journal-title":"Br J Pharmacol"},{"key":"297_CR8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/bjc.1996.37","volume":"73","author":"I Adachi","year":"1996","unstructured":"Adachi I, Watanabe T, Takashima S, Narabayashi M, Horikoshi N, Aoyama H, et al. A late phase II study of RP 56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer. 1996;73:210\u20136.","journal-title":"Br J Cancer"},{"key":"297_CR9","first-page":"2625","volume":"21","author":"T Taguchi","year":"1994","unstructured":"Taguchi T, Mori S, Abe R, Hasegawa K, Morishita Y, Tabei T, et al. Late phase II clinical study of RP 56976 (docetaxel) in patients with advanced\/recurrent breast cancer. Gan To Kagaku Ryoho. 1994;21:2625\u201332.","journal-title":"Gan To Kagaku Ryoho"},{"key":"297_CR10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00432-007-0259-0","volume":"134","author":"M Baur","year":"2008","unstructured":"Baur M, van Oosterom AT, Dieras V, Tubiana-Hulin M, Coombes RC, Hatschek T, et al. A phase II trial of docetaxel as second-line chemotherapy in patients with metastatic breast cancer. J Cancer Res Clin Oncol. 2008;134:125\u201335.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"297_CR11","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","volume":"13","author":"PM Ravdin","year":"1995","unstructured":"Ravdin PM, Burris HA III, Cook G, Eisenberg P, Kane M, Bierman WA, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995;13(12):2879\u201385.","journal-title":"J Clin Oncol"},{"key":"297_CR12","first-page":"2453","volume":"21","author":"T Taguchi","year":"1994","unstructured":"Taguchi T, Hirata K, Kunii Y, Tabei T, Suwa T, Kitajima M, et al. An early phase II study of RP 56976 (docetaxel) in patients with breast cancer. Gan To Kagaku Ryoho. 1994;21:2453\u201360.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"2","key":"297_CR13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.1995.13.2.314","volume":"13","author":"B Chavallier","year":"1995","unstructured":"Chavallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 1995;13(2):314\u201322.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-011-0297-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-011-0297-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-011-0297-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T12:40:47Z","timestamp":1559565647000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-011-0297-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,24]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1007\/s12282-011-0297-y","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,24]]}}}